You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
EvoTech reported Q3 2026 revenue of €164.9 million and adjusted EBITDA of minus 1.6 million euros, near break-even. Vertex Pharmaceuticals selected EvoTech for commercial manufacturing, and 2026 revenue and adjusted ABDA are expected toward the upper end of guidance ranges.
Evotec SE reported nine-month 2026 revenue of €465.0 million, down 13.1% from €535.1 million, while reaffirming full-year 2026 revenue guidance of €570 to €610 million and adjusted Group EBITDA of -€105 to -€70 million. Horizon transformation is ahead of plan.
Evotec SE appointed Dr. Joanna Holbrook Chief Scientific Officer and Management Board member effective November 1, 2026; Government of Abu Dhabi’s indirect voting stake fell from 5,62 % to 0,00 % on 09/10/2026.
Evotec SE expects first nine months of 2026 revenue of approximately €465.0 million and adjusted Group EBITDA of approximately -€42.8 million, above market expectations, and reaffirms full-year 2026 guidance.
Evotec SE announced that Chief Scientific Officer Dr. Cord Dohrmann will step down effective September 30, 2026 by mutual consent; he has served since 2010, and the search for his replacement is ongoing.
Evotech said its commercial transformation is improving net orders, inquiries and proposals, while its strategic review remains ongoing and no transaction decisions have been made.
evotech maintained high confidence in guidance of 570 to 610 million revenue and 70 to 105 million EBITDA loss; savings are on track, and the strategic review has produced no transaction decisions.
